LT3227311T - Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenai - Google Patents
Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenaiInfo
- Publication number
- LT3227311T LT3227311T LTEPPCT/US2015/064051T LT15064051T LT3227311T LT 3227311 T LT3227311 T LT 3227311T LT 15064051 T LT15064051 T LT 15064051T LT 3227311 T LT3227311 T LT 3227311T
- Authority
- LT
- Lithuania
- Prior art keywords
- domains
- antibodies
- modified
- variable fragments
- nkg2d ligands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462088456P | 2014-12-05 | 2014-12-05 | |
PCT/US2015/064051 WO2016090278A2 (en) | 2014-12-05 | 2015-12-04 | Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3227311T true LT3227311T (lt) | 2022-02-25 |
Family
ID=56092677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2015/064051T LT3227311T (lt) | 2014-12-05 | 2015-12-04 | Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenai |
Country Status (15)
Country | Link |
---|---|
US (2) | US11453713B2 (lt) |
EP (3) | EP4043474A1 (lt) |
JP (5) | JP2017537617A (lt) |
AU (2) | AU2015357578B2 (lt) |
CA (2) | CA2963274C (lt) |
DK (1) | DK3227311T3 (lt) |
ES (1) | ES2907467T3 (lt) |
HR (1) | HRP20220531T1 (lt) |
HU (1) | HUE058851T2 (lt) |
LT (1) | LT3227311T (lt) |
PL (1) | PL3227311T3 (lt) |
PT (1) | PT3227311T (lt) |
RS (1) | RS63149B1 (lt) |
SI (1) | SI3227311T1 (lt) |
WO (1) | WO2016090278A2 (lt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6853250B2 (ja) * | 2015-08-04 | 2021-03-31 | ザイフォス バイオサイエンスィズ インコーポレーテッド | 抗体の挿入可能な可変フラグメント及びnkg2dリガンドの改変されたa1−a2ドメイン、及び非天然のnkg2d受容体に結合する非天然のnkg2dリガンド |
JP2019523016A (ja) * | 2016-06-24 | 2019-08-22 | サイフォス、バイオサイエンシズ、インコーポレイテッドXyphos Biosciences Inc. | 抗体の挿入可能な可変フラグメントおよびnkg2dリガンドの改変型a1−a2ドメイン |
CN107964041B (zh) * | 2016-10-20 | 2023-08-01 | 中国科学院广州生物医药与健康研究院 | 高稳定性和高亲和力的dmic及其制法 |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
KR20190120782A (ko) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
CL2017003503A1 (es) * | 2017-12-29 | 2018-06-01 | Univ Chile | Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a). |
AU2019218136A1 (en) | 2018-02-08 | 2020-08-13 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
BR112021008617A2 (pt) * | 2018-11-05 | 2021-08-10 | Xyphos Biosciences Inc. | receptores de nkg2d não naturais que não sinalizam diretamente as células às quais eles estão ligados |
JP2022520978A (ja) * | 2019-02-18 | 2022-04-04 | クーリエ セラピューティクス インコーポレイテッド | オルソポックスウイルス主要組織適合性複合体(mhc)クラスi様タンパク質(omcp)と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質 |
US20230126689A1 (en) | 2020-03-06 | 2023-04-27 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
WO2022187591A1 (en) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
EP4380604A1 (en) | 2021-08-05 | 2024-06-12 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
TW202328188A (zh) | 2021-09-03 | 2023-07-16 | 美商Go治療公司 | 抗醣化-cmet抗體及其用途 |
AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
AU742757C (en) | 1997-12-17 | 2007-05-17 | Immunex Corporation | Cell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides |
CN1294148C (zh) * | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
AU2006338562A1 (en) * | 2005-11-03 | 2007-08-30 | Genentech, Inc. | Therapeutic anti-HER2 antibody fusion polypeptides |
EP2106446A4 (en) * | 2007-01-10 | 2010-06-16 | Univ Saskatchewan | STABILIZATION OF CYCLIC PEPTIDE STRUCTURES |
WO2012091756A1 (en) * | 2010-12-30 | 2012-07-05 | Avidbiotics Corp. | Non-natural mic proteins |
US8796420B2 (en) * | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
RU2444570C1 (ru) | 2010-06-23 | 2012-03-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф.Гамалеи" Министерства здравоохранения и социального развития Российской Федерации | Способ получения рекомбинантной вакцины |
EP2658867B1 (en) | 2010-12-30 | 2018-02-28 | Avidbiotics Corp. | Non-natural mic proteins |
TWI408370B (zh) | 2011-05-19 | 2013-09-11 | Univ Chang Gung | 胰臟癌之血清生物檢測標誌及其應用 |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
CA2862101A1 (en) * | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
US11117969B2 (en) * | 2014-12-05 | 2021-09-14 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands |
JP6853250B2 (ja) * | 2015-08-04 | 2021-03-31 | ザイフォス バイオサイエンスィズ インコーポレーテッド | 抗体の挿入可能な可変フラグメント及びnkg2dリガンドの改変されたa1−a2ドメイン、及び非天然のnkg2d受容体に結合する非天然のnkg2dリガンド |
UA123323C2 (uk) * | 2016-05-02 | 2021-03-17 | Ф. Хоффманн-Ля Рош Аг | Димерний злитий поліпептид |
-
2015
- 2015-12-04 HR HRP20220531TT patent/HRP20220531T1/hr unknown
- 2015-12-04 EP EP21214432.3A patent/EP4043474A1/en active Pending
- 2015-12-04 RS RS20220389A patent/RS63149B1/sr unknown
- 2015-12-04 US US14/959,745 patent/US11453713B2/en active Active
- 2015-12-04 LT LTEPPCT/US2015/064051T patent/LT3227311T/lt unknown
- 2015-12-04 HU HUE15864650A patent/HUE058851T2/hu unknown
- 2015-12-04 WO PCT/US2015/064051 patent/WO2016090278A2/en active Application Filing
- 2015-12-04 EP EP22168795.7A patent/EP4079747A1/en active Pending
- 2015-12-04 ES ES15864650T patent/ES2907467T3/es active Active
- 2015-12-04 JP JP2017526866A patent/JP2017537617A/ja active Pending
- 2015-12-04 CA CA2963274A patent/CA2963274C/en active Active
- 2015-12-04 DK DK15864650.5T patent/DK3227311T3/da active
- 2015-12-04 AU AU2015357578A patent/AU2015357578B2/en active Active
- 2015-12-04 PL PL15864650T patent/PL3227311T3/pl unknown
- 2015-12-04 EP EP15864650.5A patent/EP3227311B1/en active Active
- 2015-12-04 SI SI201531804T patent/SI3227311T1/sl unknown
- 2015-12-04 CA CA3204990A patent/CA3204990A1/en active Pending
- 2015-12-04 PT PT158646505T patent/PT3227311T/pt unknown
-
2018
- 2018-08-31 AU AU2018223040A patent/AU2018223040B2/en active Active
-
2020
- 2020-03-30 JP JP2020060639A patent/JP7132967B2/ja active Active
- 2020-03-30 JP JP2020061428A patent/JP7457558B2/ja active Active
- 2020-03-30 JP JP2020061413A patent/JP7083862B2/ja active Active
-
2022
- 2022-03-31 JP JP2022060245A patent/JP2022093353A/ja active Pending
- 2022-09-13 US US17/931,596 patent/US20230002475A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7132967B2 (ja) | 2022-09-07 |
EP4043474A1 (en) | 2022-08-17 |
CA2963274C (en) | 2024-01-30 |
JP2020114239A (ja) | 2020-07-30 |
US20230002475A1 (en) | 2023-01-05 |
JP2022093353A (ja) | 2022-06-23 |
JP7083862B2 (ja) | 2022-06-13 |
AU2018223040B2 (en) | 2020-04-30 |
CA2963274A1 (en) | 2016-06-09 |
ES2907467T3 (es) | 2022-04-25 |
PL3227311T3 (pl) | 2022-05-16 |
AU2015357578B2 (en) | 2018-11-08 |
SI3227311T1 (sl) | 2022-04-29 |
CA3204990A1 (en) | 2016-06-09 |
AU2018223040A1 (en) | 2018-09-20 |
RS63149B1 (sr) | 2022-05-31 |
JP2020114238A (ja) | 2020-07-30 |
DK3227311T3 (da) | 2022-03-07 |
US20160159882A1 (en) | 2016-06-09 |
PT3227311T (pt) | 2022-02-23 |
HUE058851T2 (hu) | 2022-09-28 |
WO2016090278A3 (en) | 2016-07-28 |
JP2017537617A (ja) | 2017-12-21 |
JP7457558B2 (ja) | 2024-03-28 |
AU2015357578A1 (en) | 2017-04-13 |
JP2020114854A (ja) | 2020-07-30 |
EP3227311B1 (en) | 2022-02-02 |
EP3227311A4 (en) | 2018-08-01 |
US11453713B2 (en) | 2022-09-27 |
WO2016090278A2 (en) | 2016-06-09 |
EP3227311A2 (en) | 2017-10-11 |
EP4079747A1 (en) | 2022-10-26 |
HRP20220531T1 (hr) | 2022-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE058851T2 (hu) | Inzertálható variábilis antitestfragmentumok és az NKG2D ligandumok módosított A1-A2 doménjei | |
HK1252698A1 (zh) | 抗siglec-9抗體及其使用方法 | |
IL259495A (en) | Antibodies and methods for using them | |
IL254887A0 (en) | Anti-sortilin antibodies and methods of using them | |
IL258397A (en) | Anti-aging antibodies and methods of using them | |
HK1252696A1 (zh) | 抗siglec-7抗體及其使用方法 | |
SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
IL252837B (en) | fcrn antibodies and methods of using them | |
HK1254743A1 (zh) | 新穎抗密封蛋白抗體及使用方法 | |
IL248399A0 (en) | New anti-43rnf antibodies and methods of use | |
IL264528B1 (en) | fcrn antibodies and methods of using them | |
IL270793A (en) | Anti-HTRA1 antibodies and methods of using them | |
ZA201701674B (en) | Novel anti-mfi2 antibodies and methods of use |